Analyst Opinion Summary: Xenetic Biosciences, Inc. (XBIO), BroadVision, Inc. (BVSN)

Xenetic Biosciences, Inc. (NASDAQ:XBIO) tinted gains of +1.35% (+0.03 points) to US$2.24. The volume of 0.13 Million shares climbed down over an trading activity of 57.28 Million shares. EPS ratio determined by looking at last 12 month figures is -0.12. Over the same time span, the stock marked US$8.95 as its best level and the lowest price reached was US$1.37. The corporation has a market cap of US$21.44 Million.

Xenetic Biosciences, Inc. (NASDAQ:XBIO)’s earnings per share has been growing at a -13.7 percent rate over the past 5 year when average revenue increase was noted as 139.2 percent. The return on equity ratio or ROE stands at -9.5 percent while most common profitability ratio return on investment (ROI) was -25 percent. The company’s institutional ownership is monitored at 1.1 percent. The company’s net profit margin has achieved the current level of -16.2 percent and possesses 0 percent gross margin.

BroadVision, Inc. (NASDAQ:BVSN) is worth US$8.03 Million and has recently fallen -2.52% to US$1.55. The latest exchange of 0.12 Million shares is below its average trading activity of 16.14 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$3.15 while the mean 12-month price target for the shares is US$0.

Currently, the stock carries a price to earnings ratio of 0.1, a price to book ratio of 2.63, and a price to sales ratio of 1.51. For the past 5 years, the company’s revenue has grown -15.9%, while the company’s earnings per share has grown 72.5%. With an institutional ownership near 5.3%, it carries an earnings per share ratio of 14.86.